-
Media ReleaseNovartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries
-
Media ReleaseFDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
-
Media ReleaseNovartis' new heart failure medicine LCZ696 approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization; now called Entresto™ (sacubitril/valsartan)
-
Media ReleaseNovartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
-
Media ReleasePatients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®
-
Media ReleaseUp to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
-
Media ReleaseApproximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
-
Media ReleaseFDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media ReleaseNovartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
-
Media ReleaseNovartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney’s Office for the Southern District of New York
-
Media ReleaseNovartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows